finnish
new
variant
chlamydia
trachomati
finvct
escap
diagnost
finland
norway
sweden
develop
valid
aptimaformat
nucleic
acid
amplif
test
naat
design
specif
detect
finvct
naat
high
sensit
specif
finvct
strain
enabl
investig
geograph
distribut
preval
transmiss
diagnosticescap
mutant
screen
popul
europ
februari
investig
discrep
nucleic
acid
amplif
test
naat
result
led
discoveri
new
genet
variant
strain
chlamydia
trachomati
southwestern
finland
strain
design
finnish
new
variant
c
trachomati
finvct
harbour
singl
nt
base
mutat
escherichia
coli
number
rrna
mutat
determin
root
caus
compromis
detect
organ
aptima
combo
diagnost
test
holog
inc
san
diego
california
unit
state
us
target
c
trachomati
rrna
archiv
newli
receiv
clinic
specimen
finland
sweden
equivoc
result
highneg
rel
light
unit
rlu
test
discrep
result
target
rrna
separ
aptima
chlamydia
trachomati
act
test
target
rrna
ie
negativeequivocalact
posit
signal
presenc
new
strain
data
collect
subsequ
investig
suggest
recent
emerg
finvct
southwestern
finland
norway
sweden
rel
low
preval
ca
among
patient
c
trachomati
infect
develop
valid
researchus
aptimaformat
surveil
naat
design
specif
detect
finvct
strain
assay
facilit
investig
determin
geograph
distribut
preval
transmiss
diagnosticescap
mutant
understand
geograph
distribut
preval
transmiss
dynam
finvct
strain
nation
intern
develop
aptimaformat
naat
sensit
specif
detect
finvct
rrna
gene
mutat
wildtyp
c
trachomati
strain
researchus
test
use
target
captur
transcriptionmedi
amplif
chemistri
autom
panther
instrument
holog
inc
isol
amplifi
c
trachomati
rrna
acridinium
ester
probe
select
detect
mutat
posit
valid
verif
studi
new
finvct
assay
conduct
accord
clinic
laboratori
standard
institut
clsi
standard
protocol
use
vitro
diagnost
assay
valid
cutoff
valu
test
rlu
initi
establish
test
deidentifi
remnant
clinic
specimen
obtain
larg
refer
laboratori
us
collect
consist
specimen
endocerv
vagin
swab
male
femal
urin
preservcyt
thinprep
liquid
cytolog
posit
c
trachomati
assay
specimen
mix
type
finnish
new
variant
chlamydia
trachomati
finvct
escap
diagnost
finland
norway
sweden
develop
valid
aptimaformat
nucleic
acid
amplif
test
naat
design
specif
detect
finvct
naat
high
sensit
specif
finvct
strain
enabl
investig
geograph
distribut
preval
transmiss
diagnosticescap
mutant
screen
popul
europ
februari
investig
discrep
nucleic
acid
amplif
test
naat
result
led
discoveri
new
genet
variant
strain
chlamydia
trachomati
southwestern
finland
strain
design
finnish
new
variant
c
trachomati
finvct
harbour
singl
nt
base
mutat
escherichia
coli
number
rrna
mutat
determin
root
caus
compromis
detect
organ
aptima
combo
diagnost
test
holog
inc
san
diego
california
unit
state
us
target
c
trachomati
rrna
archiv
newli
receiv
clinic
specimen
finland
sweden
equivoc
result
highneg
rel
light
unit
rlu
test
discrep
result
target
rrna
separ
aptima
chlamydia
trachomati
act
test
target
rrna
ie
negativeequivocalact
posit
signal
presenc
new
strain
data
collect
subsequ
investig
suggest
recent
emerg
finvct
southwestern
finland
norway
sweden
rel
low
preval
ca
among
patient
c
trachomati
infect
develop
valid
researchus
aptimaformat
surveil
naat
design
specif
detect
finvct
strain
assay
facilit
investig
determin
geograph
distribut
preval
transmiss
diagnosticescap
mutant
understand
geograph
distribut
preval
transmiss
dynam
finvct
strain
nation
intern
develop
aptimaformat
naat
sensit
specif
detect
finvct
rrna
gene
mutat
wildtyp
c
trachomati
strain
researchus
test
use
target
captur
transcriptionmedi
amplif
chemistri
autom
panther
instrument
holog
inc
isol
amplifi
c
trachomati
rrna
acridinium
ester
probe
select
detect
mutat
posit
valid
verif
studi
new
finvct
assay
conduct
accord
clinic
laboratori
standard
institut
clsi
standard
protocol
use
vitro
diagnost
assay
valid
cutoff
valu
test
rlu
initi
establish
test
deidentifi
remnant
clinic
specimen
obtain
larg
refer
laboratori
us
collect
consist
specimen
endocerv
vagin
swab
male
femal
urin
preservcyt
thinprep
liquid
cytolog
posit
c
trachomati
assay
specimen
mix
type
figur
signaltocutoff
sco
ratio
valu
clinic
specimen
test
rang
mean
sco
ratio
valu
rang
c
trachomati
wild
type
specimen
equal
specimen
neg
c
trachomati
neg
control
includ
analysi
n
consist
copiesml
wild
type
c
trachomati
rna
yield
sco
ratio
valu
rang
mean
posit
control
n
consist
copiesml
ivt
rna
correspond
finvct
rrna
yield
co
ratio
valu
rang
mean
data
shown
analyt
sensit
new
aptimaformat
finvct
surveil
assay
detect
vitro
transcript
ivt
rna
contain
c
trachomati
rrna
mutat
use
rlu
cutoff
establish
probit
analysi
panel
six
posit
one
neg
finvct
rna
sampl
n
replic
panel
member
figur
analysi
establish
limit
detect
lod
assay
copiesml
aptima
sampl
transport
medium
copiesml
urin
sampl
matrix
equival
ca
infecti
unit
per
ml
ifuml
ifuml
respect
copi
ifu
convers
data
shown
analyt
specif
crossreact
interfer
spike
recoveri
assay
nontarget
organ
potenti
encount
urogenit
extragenit
specimen
assess
test
minimum
ten
replic
pool
consist
organ
per
pool
encompass
bacteri
yeast
protozo
viral
speci
high
titr
tabl
nontarget
organ
test
yield
neg
result
assay
assess
nontarget
organ
interfer
rrna
ivt
rna
spike
concentr
three
time
assay
lod
copiesml
test
presenc
high
titr
pool
result
posit
rrna
specimen
tabl
except
panel
posit
addit
cultur
isol
c
trachomati
serotyp
b
ba
c
e
f
g
h
j
k
contain
wild
type
base
rrna
test
ifuml
except
serotyp
g
test
ifuml
serotyp
test
n
replic
yield
neg
result
assay
sco
ratio
valu
rang
data
shown
addit
valid
studi
aptimaformat
finvct
surveil
assay
use
spike
specimen
clinic
specimen
perform
world
health
organ
collabor
centr
gonorrhoea
sexual
transmit
infect
sweden
result
valid
summaris
tabl
briefli
neisseria
gonorrhoea
refer
strain
isol
nonn
gonorrhoea
neisseria
speci
three
moraxella
speci
trichomona
vaginali
tv
sampl
includ
two
tv
atcc
strain
five
refer
strain
four
nontv
trichomona
speci
nine
c
trachomati
strain
differ
genotyp
swedish
new
variant
c
trachomati
senvct
four
nonc
trachomati
chlamydia
speci
clinic
c
trachomati
wild
type
posit
specimen
clinic
specimen
posit
n
gonorrhoea
vaginali
bacteri
vaginosi
candida
speci
clinic
specimen
neg
finvct
assay
howev
finvct
posit
clinic
specimen
verifi
rrna
gene
sequenc
posit
new
aptimaformat
finvct
surveil
assay
tabl
studi
present
valid
verif
data
new
researchus
aptimaformat
naat
detect
finvct
strain
assay
select
detect
high
sensit
specif
c
trachomati
strain
contain
rrna
mutat
found
root
caus
compromis
detect
assay
detect
c
trachomati
strain
lack
nt
varianc
genet
variat
c
trachomati
highli
preval
bacteri
sti
histor
consid
uncommon
howev
recent
largescal
genom
analysi
geograph
tempor
divers
c
trachomati
strain
reveal
remark
degre
homolog
recombin
mutat
occur
organ
recent
millennia
new
understand
provid
addit
insight
previou
discoveri
diagnosticescap
mutant
c
trachomati
spread
undetect
sweden
year
discoveri
senvct
delet
plasmid
dna
target
two
wide
use
diagnost
naat
use
time
allow
senvct
strain
reach
high
preval
level
segment
infect
popul
autom
researchus
aptimaformat
finvct
surveil
test
describ
facilit
rapid
complet
epidemiolog
surveil
studi
estim
finvct
preval
track
geograph
tempor
spread
new
diagnosticescap
variant
peopl
screen
sti
europ
probit
lod
valu
detect
rna
contain
sequenc
copiesml
urin
specimen
copiesml
sampl
transport
medium
stm
specimen
cross
reactiv
interfer
test
nontarget
organ
aptimaformat
finnish
new
variant
chlamydia
trachomati
finvct
surveil
assay
panther
instrument
unit
state
tabl
cross
reactiv
nontarget
organ
spike
sampl
detect
clinic
specimen
aptimaformat
finnish
new
variant
chlamydia
trachomati
finvct
surveil
assay
panther
instrument
europ
bacteri
speci
specimen
number
test
finvct
posit
finvct
neg
